FDA Approves Isatuximab-irfc for Subcutaneous Injection for Multiple Myeloma Indications By Ogkologos - August 19, 2026 55 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IRAKLIA, IZALCO and IsaSocut studies Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Metastatic Breast Cancer: ESMO Clinical Practice Guideline May 29, 2026 EMA Recommends Granting a Marketing Authorisation for Lutetium (177Lu) Vipivotide Tetraxetan October 19, 2022 Dog Finds Woman’s Lost Wedding Ring At The Beach August 18, 2021 A celebration of peer review September 21, 2021 Load more HOT NEWS Engaging People with Low-Grade Glioma in Cancer Research FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for... Cabozantinib Improves PFS in Patients with Previously Treated, Progressive Advanced Extrapancreatic... FDA Grants Regular Approval to Dostarlimab-gxly for dMMR Endometrial Cancer
